Status:
COMPLETED
Intensive Viral Dynamics Substudy of A5248
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Treatment Naive
Eligibility:
All Genders
18+ years
Brief Summary
The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The main study will estimate the viral load decay rate ...
Detailed Description
Recent data suggest that early virologic response to HIV interventions may be predictive of long-term virologic outcomes. Defining early decay in viral load through carefully performed studies of vira...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Enrollment in A5248
- Willing and able to provide informed consent
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00852618
Start Date
May 1 2008
End Date
September 1 2008
Last Update
November 1 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Hospital CRS
Aurora, Colorado, United States, 80045
2
IHV Baltimore Treatment CRS
Baltimore, Maryland, United States, 21201
3
Johns Hopkins University CRS
Baltimore, Maryland, United States, 21205
4
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts, United States, 02115